Abivax - ADR opened lower at $91.00, compared with its previous close of $91.44. In the last trading session, the stock traded between $90.00 and $92.35. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 4 years ago in Abivax - ADR is now worth
$ 1,087.05
Giving a profit of
$ 987.05 (987.05%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 9 Analysts
Buy
88.89%
Hold
11.11%
Sell
0%
Markets Today
Today's Change
$-1.22 (-1.33%)
Day High
$92.35
Day Low
$90.00
Day Open
$91.00
Prev Close
$91.44
Volume
6,11,175
1W Return
0.91%
1M Return
3.82%
3M Return
-29.02%
6M Return
-26.12%
1Y Return
-17.27%
Fundamentals
Market Cap ($ Mn)
7,899
PE Ratio
-
PB Ratio
18.26
PEG Ratio
-
ROE
-176.50%
ROCE
-120.55%
EPS (TTM)
-
Investment Returns
1 Week
0.91%
1 Month
3.82%
3 Months
-29.02%
6 Months
-26.12%
9 Months
-26.51%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
14Sep
Abivax H1FY26 Results: Loss expected at $1.08 per share
Abivax reports H1 earnings on Sept 21; loss of $1.08/share expected. Revenue forecast at $1.86 million for the period. Shares rose 2.3% to $118.64 ahead of the release. Positive pre-NDA FDA interaction for Obefazimod announced July 30. Multiple analysts raised price targets between June and July 2026.
1mo ago
10Jul
Piper Sandler raises Abivax price target to $175
Piper Sandler analyst Allison Bratzel maintained an Overweight rating on Abivax (NASDAQ: ABVX) and raised the price target to $175 from $165, signaling confidence in the stock's future performance.
4mo ago
1Jul
Jefferies upgrades Abivax to Buy, raises target to $158
Jefferies upgraded Abivax to Buy with a $158 target, joining BTIG and Wedbush in raising price targets. BTIG set a target of $175 with a Buy rating, while Wedbush maintained a Neutral rating with a $110 target.
4mo ago
16Jun
BTIG reiterates Buy on Abivax, maintains $150 target
BTIG analyst Julian Harrison has reiterated a Buy rating for Abivax (NASDAQ: ABVX) and maintained a $150 price target. The move reflects continued confidence in the company's growth prospects.
